We write about change — about impact and consequences, about discoveries and the people behind them. This time, we introduce you to Roosmarijn Vandenbroucke, a discovery scientist at IRC-VIB and a professor at Ghent University. She gives us an eagle’s-eye view of her group’s latest research, which has the potential to impact the management of patients with neurodegenerative and neuroinflammatory diseases.
Houston (Texas, USA) has been home to Jeroen Pollet since August 2011. He arrived as a Fulbright scholar; now he is an assistant professor at Baylor College of Medicine (BCM), and also the director of the Formulation Development Unit at the Sabin Vaccine Institute & Texas Children`s Hospital Center for Vaccine Development. In these roles, he develops new vaccines against neglected tropical diseases and studies the interactions of vaccine antigens with immunostimulatory agents in relation to immune responses and vaccine efficacy.
A first case of colistin resistance has been described in the US. This is troubling news, since colistin is used as a last-resort drug in combating infections with highly antibiotic-resistant bacteria. The intensive use of colistin in the pork industry, mainly in China, is suspected to have caused the development of this resistance. Now, the trait is spreading rapidly; does this herald the beginning of a post-antibiotics era?
We write about change — about impact and consequences, about discoveries and the people behind them. This time, we introduce you to Roosmarijn Vandenbroucke, a discovery scientist at IRC-VIB and a professor at Ghent University. She gives us an eagle’s-eye view of her group’s latest research, which has the potential to impact the management of patients with neurodegenerative and neuroinflammatory diseases.
Houston (Texas, USA) has been home to Jeroen Pollet since August 2011. He arrived as a Fulbright scholar; now he is an assistant professor at Baylor College of Medicine (BCM), and also the director of the Formulation Development Unit at the Sabin Vaccine Institute & Texas Children`s Hospital Center for Vaccine Development. In these roles, he develops new vaccines against neglected tropical diseases and studies the interactions of vaccine antigens with immunostimulatory agents in relation to immune responses and vaccine efficacy.
A first case of colistin resistance has been described in the US. This is troubling news, since colistin is used as a last-resort drug in combating infections with highly antibiotic-resistant bacteria. The intensive use of colistin in the pork industry, mainly in China, is suspected to have caused the development of this resistance. Now, the trait is spreading rapidly; does this herald the beginning of a post-antibiotics era?